Search Results - "Ware, Joseph A."

Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium by Evers, Raymond, Piquette‐Miller, Micheline, Polli, Joseph W., Russel, Frans G.M., Sprowl, Jason A., Tohyama, Kimio, Ware, Joseph A., Wildt, Saskia N., Xie, Wen, Brouwer, Kim L.R.

“…Drug transporters are critically important for the absorption, distribution, metabolism, and excretion (ADME) of many drugs and endogenous compounds…”
Get full text

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design by Lee, Caroline A, O'Connor, Meeghan A, Ritchie, Tasha K, Galetin, Aleksandra, Cook, Jack A, Ragueneau-Majlessi, Isabelle, Ellens, Harma, Feng, Bo, Taub, Mitchell E, Paine, Mary F, Polli, Joseph W, Ware, Joseph A, Zamek-Gliszczynski, Maciej J

“…Breast cancer resistance protein (BCRP; ABCG2) limits intestinal absorption of low-permeability substrate drugs and mediates biliary excretion of drugs and…”
Get full text

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development by Smelick, Gillian S, Heffron, Timothy P, Chu, Laura, Dean, Brian, West, David A, DuVall, Scott L, Lum, Bert L, Budha, Nageshwar, Holden, Scott N, Benet, Leslie Z, Frymoyer, Adam, Dresser, Mark J, Ware, Joseph A

“…Acid-reducing agents (ARAs) are the most commonly prescribed medications in North America and Western Europe. There are currently no data describing the…”
Get full text

Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice by Shukla, Suneet, Zaher, Hani, Hartz, Anika, Bauer, Björn, Ware, Joseph A, Ambudkar, Suresh V

“…Purpose To evaluate the in vivo efficacy of curcumin as an inhibitor of the multidrug-resistance-linked ATP Binding Cassette (ABC) drug transporter, ABCG2…”
Get full text

Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy by Reyner, Eric, Lum, Bert, Jing, Jing, Kagedal, Matts, Ware, Joseph A., Dickmann, Leslie J.

“…Pharmacokinetic (PK) variability in cancer clinical trials may be due to heterogeneous populations and identifying sources of variability is important. Use of…”
Get full text

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor by WONG, Harvey, VERNILLET, Laurent, HOEFLICH, Klaus P, YONGCHANG SHI, AFTAB, Blake T, AOYAMA, Ron, TAN LAM, Sanh, BELVIN, Marcia, PRESCOTT, John, PETERSON, Amy, WARE, Joseph A, LEE, Lillian, MARTINI, Jean-Francois, PEIWEN YU, CONGFEN LI, DEL ROSARIO, Geoffrey, CHOO, Edna F

“…GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor…”
Get full text

Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors by Gadkar, Kapil, Friedrich, Christina, Hurez, Vincent, Ruiz, Maria‐Luisa, Dickmann, Leslie, Kumar Jolly, Mohit, Schutt, Leah, Jin, Jin, Ware, Joseph A., Ramanujan, Saroja

“…Several PI3K inhibitors are in clinical development for the treatment of various forms of cancers, including pan‐PI3K inhibitors targeting all four PI3K…”
Get full text

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe by Urquhart, Bradley L, Ware, Joseph A, Tirona, Rommel G, Ho, Richard H, Leake, Brenda F, Schwarz, Ute I, Zaher, Hani, Palandra, Joe, Gregor, Jamie C, Dresser, George K, Kim, Richard B

“…Breast cancer resistance protein (BCRP) is an efflux transporter expressed in tissues that act as barriers to drug entry. Given that single nucleotide…”
Get full text

Breast Cancer Resistance Protein (Bcrp/abcg2) Is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse by Zaher, Hani, Khan, Anis A, Palandra, Joe, Brayman, Timothy G, Yu, Linning, Ware, Joseph A

“…Sulfasalazine is used in the treatment of ulcerative colitis, Crohn's disease, and rheumatoid arthritis. When administered orally, sulfasalazine is poorly…”
Get full text

Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin by Zaher, Hani, Meyer zu Schwabedissen, Henriette E, Tirona, Rommel G, Cox, Melissa L, Obert, Leslie A, Agrawal, Nidhi, Palandra, Joe, Stock, Jeffrey L, Kim, Richard B, Ware, Joseph A

“…Organic anion-transporting polypeptides (OATP) 1B1 and 1B3 are widely acknowledged as important and rate-limiting to the hepatic uptake of many drugs in…”
Get more information

Impact of Food and the Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of GDC-0941 in Healthy Volunteers: Bench to Bedside Investigation of pH-Dependent Solubility by Ware, Joseph A, Dalziel, Gena, Jin, Jin Y, Pellett, Jackson D, Smelick, Gillian S, West, David A, Salphati, Laurent, Ding, Xiao, Sutton, Rebecca, Fridyland, Jane, Dresser, Mark J, Morrisson, Glenn, Holden, Scott N

“…GDC-0941 is an orally administered potent, selective pan-inhibitor of phosphatidylinositol 3-kinases (PI3Ks) with good preclinical antitumor activity in…”
Get full text

Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis by Schwabedissen, Henriette E. Meyer zu, Ware, Joseph A., Finkelstein, David, Chaudhry, Amarjit S., Mansell, Sara, Leon‐Ponte, Matilde, Strom, Stephen C., Zaher, Hani, Schwarz, Ute I., Freeman, David J., Schuetz, Erin G., Tirona, Rommel G., Kim, Richard B.

“…The role of organic anion transporting polypeptides (OATPs), particularly the members of OATP1B subfamily, in hepatocellular handling of endogenous and…”
Get full text

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors by Sarker, Debashis, Ang, Joo Ern, Baird, Richard, Kristeleit, Rebecca, Shah, Krunal, Moreno, Victor, Clarke, Paul A, Raynaud, Florence I, Levy, Gallia, Ware, Joseph A, Mazina, Kathryn, Lin, Ray, Wu, Jenny, Fredrickson, Jill, Spoerke, Jill M, Lackner, Mark R, Yan, Yibing, Friedman, Lori S, Kaye, Stan B, Derynck, Mika K, Workman, Paul, de Bono, Johann S

“…This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics,…”
Get full text

Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo by Cheng, Linling, Stewart, Benjamin J, You, Qiang, Petersen, Dennis R, Ware, Joseph A, Piccotti, Joseph R, Kawabata, Thomas T, Ju, Cynthia

“…Immune-mediated drug hypersensitivity reactions (IDHRs) represent a significant problem due to their unpredictable and severe nature, as well as the lack of…”
Get more information

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors by Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K, Wilson, Timothy R, Ware, Joseph A, Sanabria Bohorquez, Sandra M, Savage, Heidi M, Sampath, Deepak, Salphati, Laurent, Lin, Ray S, Jin, Huan, Parmar, Hema, Hsu, Jerry Y, Von Hoff, Daniel D, Baselga, José

“…Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid…”
Get more information

STUDIES ON THE CHEMICAL REACTIVITY OF DICLOFENAC ACYL GLUCURONIDE WITH GLUTATHIONE: IDENTIFICATION OF DICLOFENAC-S-ACYL-GLUTATHIONE IN RAT BILE by GRILLO, Mark P, KNUTSON, Charles G, SANDERS, Phillip E, WALDON, Daniel J, FENGMEI HUA, WARE, Joseph A

“…Diclofenac, a nonsteroidal anti-inflammatory drug, is metabolized to a reactive acyl glucuronide that has been proposed to mediate toxic adverse drug reactions…”
Get full text

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma by Powles, Thomas, Lackner, Mark R, Oudard, Stéphane, Escudier, Bernard, Ralph, Christy, Brown, Janet E, Hawkins, Robert E, Castellano, Daniel, Rini, Brian I, Staehler, Michael D, Ravaud, Alain, Lin, Wei, O'Keeffe, Bridget, Wang, Yulei, Lu, Shan, Spoerke, Jill M, Huw, Ling-Yuh, Byrtek, Michelle, Zhu, Rui, Ware, Joseph A, Motzer, Robert J

“…To the best of our knowledge, this study is the first to compare dual inhibition of PI3K/mammalian target of rapamycin (mTOR) by apitolisib (GDC-0980) against…”
Get full text

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors by Dolly, Saoirse O, Wagner, Andrew J, Bendell, Johanna C, Kindler, Hedy L, Krug, Lee M, Seiwert, Tanguy Y, Zauderer, Marjorie G, Lolkema, Martijn P, Apt, Doris, Yeh, Ru-Fang, Fredrickson, Jill O, Spoerke, Jill M, Koeppen, Hartmut, Ware, Joseph A, Lauchle, Jennifer O, Burris, 3rd, Howard A, de Bono, Johann S

“…This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I…”
Get full text

Membrane transporters in drug development by Giacomini, Kathleen M, Huang, Shiew-Mei, Tweedie, Donald J, Benet, Leslie Z, Brouwer, Kim L R, Chu, Xiaoyan, Dahlin, Amber, Evers, Raymond, Fischer, Volker, Hillgren, Kathleen M, Hoffmaster, Keith A, Ishikawa, Toshihisa, Keppler, Dietrich, Kim, Richard B, Lee, Caroline A, Niemi, Mikko, Polli, Joseph W, Sugiyama, Yuichi, Swaan, Peter W, Ware, Joseph A, Wright, Stephen H, Yee, Sook Wah, Zamek-Gliszczynski, Maciej J, Zhang, Lei

“…Key Points Membrane transporters are increasingly being recognized as important determinants of pharmacokinetics and have been found to play a role in the…”
Get full text

Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects by Sharma, Shringi, Pepin, Xavier, Cheung, Jean, Zheng, Lianqing, Wei, Hua, Townsley, Danielle, Han, David, Majewski, Michal, Ware, Joseph A., Mann, James, Munugalavadla, Veerendra, Sheridan, Louise, Patel, Priti, Gupta, Ashok, Tomkinson, Helen

“…Aims Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukaemia. Many…”
Get full text